| Home : Ushering in the Era of Synthetic Virology: EnCapsid Therapeutics Introduces a New Dimension in AAV Engineering to Boost Infectivity and Reduce Immunogenicity in Animal Models |
|
Feb 07
2022 |
Ushering in the Era of Synthetic Virology: EnCapsid Therapeutics Introduces a New Dimension in AAV Engineering to Boost Infectivity and Reduce Immunogenicity in Animal Models |
|
BOSTON, Feb. 7, 2022 /PRNewswire/ -- EnCapsid Therapeutics Inc., the pioneer in synthetic virology, has obtained results to show that its modular and versatile capsid modification technology can be used to engineer AAV vectors with enhanced therapeutic properties. By precisely introducing... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/ushering-in-the-era-of-synthetic-virology-encapsid-therapeutics-introduces-a-new-dimension-in-aav-engineering-to-boost-infectivity-and-reduce-immunogenicity-in-animal-models-301476251.html |
| |
|
Related News
|
» Coinjoker Announces New Trading Activity Features Added On Binance Clone Script
» Record year for industrial biotechnology grants and investments
|
